447 related articles for article (PubMed ID: 28972014)
21. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
22. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
23. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
Cang S; Iragavarapu C; Savooji J; Song Y; Liu D
J Hematol Oncol; 2015 Nov; 8():129. PubMed ID: 26589495
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
[No Abstract] [Full Text] [Related]
25. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
26. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
Ahn IE; Davids MS
Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
29. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
30. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
31. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
[TBL] [Abstract][Full Text] [Related]
32. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
34. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
35. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Place AE; Goldsmith K; Bourquin JP; Loh ML; Gore L; Morgenstern DA; Sanzgiri Y; Hoffman D; Zhou Y; Ross JA; Prine B; Shebley M; McNamee M; Farazi T; Kim SY; Verdugo M; Lash-Fleming L; Zwaan CM; Vormoor J
Future Oncol; 2018 Sep; 14(21):2115-2129. PubMed ID: 29595064
[TBL] [Abstract][Full Text] [Related]
36. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Hampel PJ; Parikh SA; Call TG; Shah MV; Bennani NN; Al-Kali A; Rabe KG; Wang Y; Muchtar E; Leis JF; Kenderian SS; Koehler AB; Schwager SM; Slager SL; Kay NE; Hanson CA; Van Dyke DL; Shi M; Ding W
Blood Cancer J; 2021 Mar; 11(3):47. PubMed ID: 33654067
[No Abstract] [Full Text] [Related]
38. Prospects for Venetoclax in Myelodysplastic Syndromes.
Garcia JS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
[TBL] [Abstract][Full Text] [Related]
39. Development of venetoclax for therapy of lymphoid malignancies.
Zhu H; Almasan A
Drug Des Devel Ther; 2017; 11():685-694. PubMed ID: 28331288
[TBL] [Abstract][Full Text] [Related]
40. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Toutah K; Nawar N; Timonen S; Sorger H; Raouf YS; Bukhari S; von Jan J; Ianevski A; Gawel JM; Olaoye OO; Geletu M; Abdeldayem A; Israelian J; Radu TB; Sedighi A; Bhatti MN; Hassan MM; Manaswiyoungkul P; Shouksmith AE; Neubauer HA; de Araujo ED; Aittokallio T; Krämer OH; Moriggl R; Mustjoki S; Herling M; Gunning PT
J Med Chem; 2021 Jun; 64(12):8486-8509. PubMed ID: 34101461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]